Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters








Year range
1.
Arq. bras. neurocir ; 39(2): 116-124, 15/06/2020.
Article in English | LILACS | ID: biblio-1362499

ABSTRACT

Substance-related disorders are psychiatric conditions that have a worldwide impact. Their multifactorial cycle has been treated pharmacologically and with therapeutic support. However, high refractoriness rates and difficulty to control relapses are among the pitfalls associated with these disorders. Thus, recent studies have shown that deep brain stimulation (DBS) is a promising treatment, with a direct intervention in the neurocircuitry of addiction. The results of the present systematic review of the use of DBS for the treatment of drug addiction show that this surgical procedure can reduce the desire for the drug, and, in some cases, establish abstinence, improve psychiatric symptoms related to mood and quality of life, and reintroduce the patient into the social and family environments. Nevertheless, this approach is still limited to the academic realm, based mainly on case reports, with ethics and therapeutic protocols still to be defined. Further in-depth scientific investigations are required to recommend its clinical application.


Subject(s)
Substance-Related Disorders/surgery , Substance-Related Disorders/rehabilitation , Deep Brain Stimulation/methods , Deep Brain Stimulation/trends , Recurrence , Brain/surgery
2.
Rev. Hosp. Clin. Univ. Chile ; 31(3): 207-215, 2020. tab, ilus
Article in Spanish | LILACS | ID: biblio-1145377

ABSTRACT

Introduction: Deep brain stimulation (DBS) is a standard surgical procedure for the treatment of advanced Parkinson Disease (PD) with motor complications that cannot be adequately managed by medical treatment. Currently available literature can guide physicians on basic aspects of patients' selection and indications for DBS. However, there is a range of real-world clinical settings where the indications of DBS for Parkinson disease are debatable. Objective: to present the experience on PD patients with complex clinical manifestations treated with DBS in our hospital. Method: Report of four PD cases treated with DBS. Case 1: 63-year old woman with advanced PD and severe motor complications; Case 2: 60-year old man with 5 years of disease duration and mild motor complications; Case 3: 67-year old man with severe ventriculomegaly that may have precluded direct electrode passage to the surgical target; Case 4: 67- year-old woman with putative severe axial disability. Results: After one year of follow-up, all patients showed improvement on motor symptoms as well as quality of life. Discussion: We provide a brief rationale for the patient selection in each case to support the decision-making in the management of PD patients with complex clinical cases. (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Parkinson Disease/therapy , Deep Brain Stimulation/methods , Chile , Deep Brain Stimulation/trends , Hydrocephalus, Normal Pressure/therapy
3.
Rev. Hosp. Ital. B. Aires (2004) ; 39(2): 64-66, jun. 2019.
Article in Spanish | LILACS | ID: biblio-1048015

ABSTRACT

El trastorno obsesivo-compulsivo (TOC) afecta al 2% de la población general, llegando en ocasiones a causar un deterioro funcional severo y de la calidad de vida de las personas afectadas. Entre el 10 y el 30% de los pacientes con este trastorno no responde a los tratamientos recomendados: farmacológicos y terapia cognitivo-conductual. La Food and Drug Administration de los Estados Unidos (FDA) aprobó en el año 2008 la Estimulación cerebral profunda (ECP) para pacientes con TOC resistente a tratamiento. La ECP, utilizada frecuentemente para el tratamiento de la enfermedad de Parkinson refractaria, es una opción viable para los pacientes con TOC resistente, con efectos adversos poco frecuentes y transitorios. (AU)


Obsessive-compulsive disorder (OCD) affects 2% of the general population, sometimes resulting in severe impairment of functional capacity and quality of life of affected people. Between 10 and 30% of these patients do not respond to recommended treatments: pharmacological and cognitive behavioral therapy. In 2008, the FDA approved Deep Brain Stimulation (DBS) for patients with OCD resistant to treatment. DBS, frequently used for the treatment of refractory Parkinson's disease, is a viable option for the treatment of patients with resistant OCD, with infrequent and transient adverse effects. (AU)


Subject(s)
Humans , Deep Brain Stimulation/methods , Obsessive-Compulsive Disorder/therapy , Patient Dropouts/statistics & numerical data , Quality of Life , Signs and Symptoms , Deep Brain Stimulation/adverse effects , Deep Brain Stimulation/trends , Mental Disorders/surgery , Obsessive-Compulsive Disorder/complications , Obsessive-Compulsive Disorder/etiology , Obsessive-Compulsive Disorder/drug therapy
4.
Clin. biomed. res ; 38(4): 367-376, 2018.
Article in English | LILACS | ID: biblio-1024173

ABSTRACT

Advanced Parkinson's disease (PD) is characterized by the presence of motor fluctuations, various degrees of dyskinesia, and disability with functional impact on daily living and independence. Therapeutic management aims to extend levodopa (L-DOPA) benefit while minimizing motor complications and includes, in selected cases, the implementation of drug infusion and surgical techniques. The concept of deep brain stimulation (DBS) for PD was introduced over 20 years ago, but our understanding of the nuances of this procedure continues to improve. This review aims to demonstrate the advances of DBS in the treatment of PD patients. (AU)


Subject(s)
Humans , Parkinson Disease/therapy , Deep Brain Stimulation/adverse effects , Deep Brain Stimulation/trends , Parkinson Disease/surgery , Levodopa/therapeutic use , Pallidotomy/methods
SELECTION OF CITATIONS
SEARCH DETAIL